GSK plots major market disruption

Posted 16 September 2024 AM

GSK is positioning itself to bring the first ultra-long-acting asthma treatment to market, confirming it intends to submit depemokimab to regulators "around the world".

Administered twice-yearly, the anti-IL-5 therapy has shown to reduce asthma attacks by half and cut clinic visits by nearly three-quarters, backing up blockbuster hopes.

To see the whole article, please login